Foghorn Prices $110M Registered Direct Offering Of 12,743,039 Common Stock At A Price Of $5.51 Per Share And Pre-Funded Warrants To Purchase Up To An Aggregate Of 7,220,794 Shares Of Its Common Stock At A Price Of $5.5099 Per Pre-Funded Warrant
Foghorn Therapeutics Inc. ("Foghorn") (NASDAQ:FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions. All of the shares of common stock in the offering are to be sold by Foghorn.
Foghorn anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commissions and estimated offering expenses) will be approximately $110 million.
Foghorn intends to use the net proceeds from this offering to advance its preclinical and clinical programs and for general corporate purposes.
Jefferies, TD Cowen and Evercore ISI are acting as joint book-running managers for the proposed offering.